BR112021023209A2 - Terapia com vacina anti-abeta - Google Patents
Terapia com vacina anti-abetaInfo
- Publication number
- BR112021023209A2 BR112021023209A2 BR112021023209A BR112021023209A BR112021023209A2 BR 112021023209 A2 BR112021023209 A2 BR 112021023209A2 BR 112021023209 A BR112021023209 A BR 112021023209A BR 112021023209 A BR112021023209 A BR 112021023209A BR 112021023209 A2 BR112021023209 A2 BR 112021023209A2
- Authority
- BR
- Brazil
- Prior art keywords
- administered
- vaccine therapy
- mpla
- amyloid
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
terapia com vacina antiabeta. uma composição de vacina lipossomal, compreendendo: a. um antígeno de peptídeo derivado de ß-amiloide (aß) exibido na superfície do lipossoma que compreende, consiste essencialmente em ou consiste nos aminoácidos 1-15 de aß. b. um adjuvante compreendendo monofosforil lipídeo a (mpla) é usado para induzir uma resposta imune anti-aß em um sujeito humano sem induzir um evento adverso sério. o antígeno de peptídeo derivado de ß-amiloide (aß) (seq id no: 1) é administrado em uma quantidade de 300-2000 µg, preferencialmente em torno de 1000 µg. o mpla é administrado numa quantidade de 15-600 µg, de preferência cerca de 175 µg. a composição da vacina lipossomal é administrada por via intramuscular ou subcutânea.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19175810 | 2019-05-21 | ||
| EP19185593 | 2019-07-10 | ||
| EP20171549 | 2020-04-27 | ||
| EP20172205 | 2020-04-29 | ||
| PCT/EP2020/064172 WO2020234405A1 (en) | 2019-05-21 | 2020-05-20 | Anti-abeta vaccine therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023209A2 true BR112021023209A2 (pt) | 2022-01-18 |
Family
ID=70740677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023209A BR112021023209A2 (pt) | 2019-05-21 | 2020-05-20 | Terapia com vacina anti-abeta |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220226447A1 (pt) |
| EP (1) | EP3972633A1 (pt) |
| JP (1) | JP2022533422A (pt) |
| KR (1) | KR20220010552A (pt) |
| CN (1) | CN113853214A (pt) |
| AU (1) | AU2020277682A1 (pt) |
| BR (1) | BR112021023209A2 (pt) |
| CA (1) | CA3138145A1 (pt) |
| CL (1) | CL2021003051A1 (pt) |
| IL (1) | IL288252A (pt) |
| MX (1) | MX2021014102A (pt) |
| SG (1) | SG11202112329RA (pt) |
| TW (1) | TW202110425A (pt) |
| WO (1) | WO2020234405A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024156912A1 (en) * | 2023-01-26 | 2024-08-02 | Ac Immune Sa | Anti-abeta vaccine therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| EP1959991B1 (en) | 2005-12-12 | 2013-03-20 | AC Immune S.A. | Therapeutic vaccine |
| EP3527220A1 (en) | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Vaccine engineering |
| CA2813833C (en) | 2010-10-26 | 2020-09-22 | Ac Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| KR20160005380A (ko) | 2011-09-23 | 2016-01-15 | 에이씨 이뮨 에스.에이. | 백신 요법 |
-
2020
- 2020-05-20 TW TW109116790A patent/TW202110425A/zh unknown
- 2020-05-20 BR BR112021023209A patent/BR112021023209A2/pt unknown
- 2020-05-20 US US17/612,921 patent/US20220226447A1/en active Pending
- 2020-05-20 KR KR1020217041697A patent/KR20220010552A/ko unknown
- 2020-05-20 CA CA3138145A patent/CA3138145A1/en active Pending
- 2020-05-20 WO PCT/EP2020/064172 patent/WO2020234405A1/en active Application Filing
- 2020-05-20 CN CN202080035690.8A patent/CN113853214A/zh active Pending
- 2020-05-20 AU AU2020277682A patent/AU2020277682A1/en active Pending
- 2020-05-20 SG SG11202112329RA patent/SG11202112329RA/en unknown
- 2020-05-20 EP EP20726473.0A patent/EP3972633A1/en active Pending
- 2020-05-20 JP JP2021569155A patent/JP2022533422A/ja active Pending
- 2020-05-20 MX MX2021014102A patent/MX2021014102A/es unknown
-
2021
- 2021-11-18 CL CL2021003051A patent/CL2021003051A1/es unknown
- 2021-11-21 IL IL288252A patent/IL288252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220010552A (ko) | 2022-01-25 |
| US20220226447A1 (en) | 2022-07-21 |
| CL2021003051A1 (es) | 2022-07-22 |
| TW202110425A (zh) | 2021-03-16 |
| JP2022533422A (ja) | 2022-07-22 |
| AU2020277682A1 (en) | 2021-12-23 |
| EP3972633A1 (en) | 2022-03-30 |
| SG11202112329RA (en) | 2021-12-30 |
| CN113853214A (zh) | 2021-12-28 |
| WO2020234405A1 (en) | 2020-11-26 |
| IL288252A (en) | 2022-01-01 |
| MX2021014102A (es) | 2022-02-11 |
| CA3138145A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agger | Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates | |
| BR112018073676A2 (pt) | lipossomas peguilados e métodos de uso | |
| NZ701881A (en) | Vaccines for hsv-2 | |
| BR9509190A (pt) | Composição de vacina produto farmacêutico processos para imunizar um portador contra infecção gripal para aperfeiçoar uma resposta imune de mucosa de iga protetora e uma resposta imune sistêmica e igg e para aperfeiçoar a resposta imune de antigenos de vírus de gripe e uso de um quitosano | |
| AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
| BRPI0920791B8 (pt) | Uso de peptídeo na preparação de medicamento para tratar câncer e kit | |
| BR0108924A (pt) | Composição umonogênica adaptada para administração a um hospedeiro humano para o tratamento ou prevenção da aterosclerose, vacina, e, método de tratamento ou profilaxia da aterosclerose | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| TW200722101A (en) | Novel composition | |
| BR112021023209A2 (pt) | Terapia com vacina anti-abeta | |
| AU2012257771C1 (en) | Vaccine against Streptococcus pneumoniae | |
| JP2015500827A5 (pt) | ||
| Junqueira et al. | Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine | |
| JP6655549B2 (ja) | 免疫応答を誘導するための新規方法 | |
| BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
| BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
| JP2015529677A5 (pt) | ||
| BRPI0417225A (pt) | métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos | |
| AR053661A1 (es) | Peptido para entregar vacunas via mucosas | |
| ES2547855T3 (es) | Procedimiento de desencadenamiento o inducción de una respuesta inmunitaria | |
| CN102612559B (zh) | 源自流感m2的修饰的肽疫苗 | |
| US20190224296A1 (en) | Toll-like receptor 2 agonists and vaccines and uses thereof | |
| AU5355801A (en) | Recombinant intracellular pathogen vaccines and methods for use | |
| AR093530A1 (es) | Adyuvante de vacunacion, preparacion, y vacunas que lo contienen | |
| EA202193183A1 (ru) | Терапия с помощью вакцины против бета-амилоида |